|
 The deal is for around twice as many treatment courses as Merck & Co
Inc has agreed to supply the United States under its contract. The
price for the Pfizer pill is nearly 25%lower at roughly $530 per
course, compared with about $700 for Merck's.
Pfizer applied for emergency authorization of the drug, branded as
Paxlovid, this week after reporting data showing that it was 89%
effective at preventing hospitalization or death in at-risk people.
The trial's results suggest that Paxlovid surpasses Merck's
molnupiravir which was shown last month to halve the risk of dying
or being hospitalized for COVID-19 patients at high risk of serious
illness.
"While this pill still requires a full review by the Food and Drug
Administration, I have taken immediate steps to secure enough supply
for the American people," President Joe Biden said in a statement.
He added that his administration was making preparations to ensure
the treatment is easily accessible and free.
Pfizer said it would begin deliveries of the treatment as soon as
this year if it is authorized by the U.S. FDA.
Shares of Pfizer were up 0.65% at $51.20 on Thursday afternoon,
while shares of Merck were nearly flat at $82.63.
Getting vaccinated should still be the priority for Americans but
having pills that can keep people out of the hospital "could be a
lifesaver," said U.S. Secretary of Health and Human Services Xavier
Becerra.
[to top of second column] |
 Pfizer has said it expects to
manufacture 180,000 treatment courses by the end
of next month and at least 50 million courses by
the end of 2022.
Countries have scrambled to secure doses of the
Pfizer and Merck oral drugs, based on promising
data reported by both companies.
The U.S. government has so far secured 3.1
million courses of Merck's COVID-19 pill for
$2.2 billion, with the right to buy 2 million
more courses in the future.
Drugs in the same class as Merck's pill have
been linked to birth defects in animal studies.
Merck has said similar studies of its drug - for
longer and at higher doses than used in humans -
show that it does not cause birth defects or
cancer.
(Reporting by Manas Mishra in Bengaluru,
Additional reporting by Michael Erman in New
Jersey; Editing by Ramakrishnan M. and Matthew
Lewis)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
 |
